Visión generalGráficoTécnicoNoticiasTraderScreen

XBiotech Inc/  CA98400H1029  /

NASDAQ
07/11/2024  17:05:36 Diferencia -0.0950 Volumen Bid17:07:53 Ask17:07:53 Máximo del día Price Change Band
8.1550USD -1.15% 22,833
Volumen de negocios: 118,089.5640		 8.1300Volumen de oferta: 200 8.2500Tamaño/ Volumen/ Formato de Ask: 2,200 8.2500 7.9215
GlobeNewswire 18/06 XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treat...
GlobeNewswire 04/01 XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
GlobeNewswire 04/01 XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
GlobeNewswire 14/11/2023 Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
GlobeNewswire 26/09/2023 XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate T...
GlobeNewswire 30/08/2023 XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natr...
GlobeNewswire 26/01/2022 XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natr...
GlobeNewswire 13/12/2021 FDA Approves XBiotech’s IND in Rheumatology
GlobeNewswire 11/12/2021 Annual Changes to the Nasdaq Biotechnology Index
GlobeNewswire 28/10/2021 XBiotech to Launch Novel Candidate Therapy for Stroke
GlobeNewswire 08/09/2021 Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in ...
GlobeNewswire 30/08/2021 XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director
GlobeNewswire 30/07/2021 XBiotech Announces Payment of Dividend to Holders of Common Stock
GlobeNewswire 06/07/2021 XBiotech Announces Dividend to Holders of Common Stock
GlobeNewswire 30/06/2021 XBiotech Announces Receipt of $75 Million from Sale of Antibody
GlobeNewswire 23/06/2021 XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of P...
GlobeNewswire 03/05/2021 French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptiv...
GlobeNewswire 19/04/2021 FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled S...
GlobeNewswire 21/01/2021 XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain
GlobeNewswire 19/01/2021 XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
GlobeNewswire 19/11/2020 XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influen...
GlobeNewswire 21/09/2020 XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co...
GlobeNewswire 24/08/2020 XBiotech-Developed COVID-19 Test Supports Convalescent Blood Treatments Now Approved Under FDA Emerg...
TeleTrader 17/08/2020 Wall Street ends mixed as Nasdaq reaches record high
TeleTrader 17/08/2020 Europe closes higher on virus treatment hopes